Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014

PHASE3CompletedINTERVENTIONAL
Enrollment

1,558

Participants

Timeline

Start Date

February 13, 2008

Primary Completion Date

July 31, 2009

Study Completion Date

September 17, 2009

Conditions
Infections, Meningococcal
Interventions
BIOLOGICAL

GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)

One dose in the booster phase as intramuscular injection

BIOLOGICAL

GSK Biologicals' Hib-meningococcal vaccine GSK 792014 (Menhibrix)

Three doses in the priming phase and, for Menhibrix 2 Group, one dose in the booster phase as intramuscular injection

BIOLOGICAL

Infanrix®

One dose as intramuscular injection

BIOLOGICAL

ActHIB®

Three doses in the priming phase as intramuscular injection

BIOLOGICAL

Pediarix®

Three doses in the priming phase as intramuscular injection

Trial Locations (56)

15220

GSK Investigational Site, Pittsburgh

15236

GSK Investigational Site, Pittsburgh

15241

GSK Investigational Site, Pittsburgh

15401

GSK Investigational Site, Uniontown

16125

GSK Investigational Site, Greenville

16505

GSK Investigational Site, Erie

27609

GSK Investigational Site, Raleigh

28721

GSK Investigational Site, Clyde

29406

GSK Investigational Site, Charleston

30062

GSK Investigational Site, Marietta

30189

GSK Investigational Site, Woodstock

33324

GSK Investigational Site, Plantation

33407

GSK Investigational Site, West Palm Beach

35205

GSK Investigational Site, Birmingham

35244

GSK Investigational Site, Birmingham

36305

GSK Investigational Site, Dothan

37660

GSK Investigational Site, Kingsport

40004

GSK Investigational Site, Bardstown

40503

GSK Investigational Site, Lexington

44121

GSK Investigational Site, Cleveland

45424

GSK Investigational Site, Huber Heights

49008

GSK Investigational Site, Kalamazoo

49024

GSK Investigational Site, Portage

49083

GSK Investigational Site, Richland

49120

GSK Investigational Site, Niles

49127

GSK Investigational Site, Stevensville

50266

GSK Investigational Site, West Des Moines

50312

GSK Investigational Site, Des Moines

54449

GSK Investigational Site, Marshfield

55108

GSK Investigational Site, Saint Paul

67005

GSK Investigational Site, Arkansas City

71111

GSK Investigational Site, Bossier City

72019

GSK Investigational Site, Benton

72205

GSK Investigational Site, Little Rock

72401

GSK Investigational Site, Jonesboro

72703

GSK Investigational Site, Fayetteville

77479

GSK Investigational Site, Sugar Land

79124

GSK Investigational Site, Amarillo

84041

GSK Investigational Site, Layton

84057

GSK Investigational Site, Orem

84067

GSK Investigational Site, Roy

84075

GSK Investigational Site, Syracuse

84095

GSK Investigational Site, South Jordan

84405

GSK Investigational Site, Ogden

84604

GSK Investigational Site, Provo

84790

GSK Investigational Site, St. George

89015

GSK Investigational Site, Henderson

91790

GSK Investigational Site, West Covina

92647

GSK Investigational Site, Huntington Beach

92708

GSK Investigational Site, Fountain Valley

93726

GSK Investigational Site, Fresno

97030

GSK Investigational Site, Gresham

208 463 3126

GSK Investigational Site, Nampa

02130

GSK Investigational Site, Boston

02724

GSK Investigational Site, Fall River

77555-1119

GSK Investigational Site, Galveston

Sponsors

Lead Sponsor

All Listed Sponsors
lead

GlaxoSmithKline

INDUSTRY

NCT00614614 - Immuno,Safety of GSK Vaccine 134612 Given at Age of 12-15 Months 15-18 Months Post-priming With GSK Vaccine 792014 | Biotech Hunter | Biotech Hunter